î
îŒ
î
Cyclerion Therapeutics Inc
CYCNî¹
詳现ãã£ãŒãã衚瀺
1.100USD
+0.020+1.85%
çµå€Â 02/06, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
4.06Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+1.85%
5æ¥é
-19.12%
1ã¶æ
-38.89%
6ã¶æ
-53.29%
幎åæ¥
-13.39%
1幎é
-73.87%
詳现ãã£ãŒãã衚瀺
TradingKeyã®Cyclerion Therapeutics Incã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2026-02-06äž»èŠã€ã³ãµã€ã
Cyclerion Therapeutics Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å šã§ããæ¥çããªãŒãããESGé瀺ãšãšãã«ãæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç 究æ¥çã§ã®é äœã¯392äž199äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§éåžžã«äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã¯å 調ã§ããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Cyclerion Therapeutics Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¡ãã£ã¢å ±é
éå»24æé
å ±éã¬ãã«
éåžžã«äœã
éåžžã«é«ã
äžç«
Cyclerion Therapeutics Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
é«æé·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§573.40%ã®æé·çã瀺ããŠããŸãã
æé·äž
å瀟ã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 2.00Mã«éããŠããŸãã
é©æ£æ°Žæº
å瀟ã®ææ°ã®PEã¯-1.56ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé©æ£åã«ãããŸãã
ãã³ã¬ãŒããä¿æ
ã¹ã¿ãŒæè³å®¶ãã³ã¬ãŒãã¯æ¬éæã23.49Kæ ªä¿æããŠããŸãã
ã¢ããªã¹ãè©äŸ¡
0
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
--
çŸåšã®è©äŸ¡
--
ç®æšæ ªäŸ¡
--
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
Cyclerion Therapeutics Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Cyclerion Therapeutics Incã®äŒæ¥æ å ±î
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
äŒæ¥ã³ãŒãCYCN
äŒæ¥åCyclerion Therapeutics Inc
æé«çµå¶è²¬ä»»è
ãCEOãGraul (Regina M)
ãŠã§ããµã€ãhttps://www.cyclerion.com/
é¢é£éèåå
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%人æ°éæ
278.120
+2.210Â (+0.80%)
185.410
+13.530Â (+7.87%)
69997.380
+396.200Â (+0.57%)
282.580
+22.390Â (+8.61%)
2086.770
-16.050Â (-0.76%)
411.110
+13.900Â (+3.50%)
4952.980
+142.360Â (+2.96%)
63.303
+0.206Â (+0.33%)
1.182
+0.004Â (+0.35%)
157.098
+0.057Â (+0.04%)
